Inhalant dependence with inhalant-induced psychotic disorder, unspecified
ICD-10 F18.259 is a billable code used to indicate a diagnosis of inhalant dependence with inhalant-induced psychotic disorder, unspecified.
Inhalant dependence with inhalant-induced psychotic disorder, unspecified, refers to a condition where an individual exhibits a compulsive pattern of inhalant use leading to significant impairment or distress, accompanied by psychotic symptoms such as hallucinations or delusions directly attributable to inhalant intoxication. Inhalants include a variety of substances such as solvents, aerosols, and gases that are inhaled for psychoactive effects. The dependence manifests through a strong desire to use inhalants, tolerance, and withdrawal symptoms when not using. The psychotic disorder may present as acute episodes of psychosis during or shortly after inhalant use, which can complicate the clinical picture. Treatment typically involves a combination of behavioral therapies, counseling, and support groups, focusing on cessation of inhalant use and management of psychotic symptoms. Given the potential for severe health consequences, including neurological damage and psychological disturbances, early intervention and comprehensive treatment plans are crucial for recovery.
Detailed psychiatric evaluation, including history of substance use and mental health status.
Patients presenting with acute psychosis following inhalant use, or chronic users with persistent psychotic symptoms.
Ensure comprehensive documentation of both inhalant use and psychotic symptoms to support the diagnosis.
Thorough assessment of substance use patterns, withdrawal symptoms, and treatment history.
Patients in detoxification programs or those seeking rehabilitation for inhalant dependence.
Focus on the impact of inhalant use on overall health and the need for multidisciplinary treatment approaches.
Used for initial evaluation of patients with suspected inhalant dependence and psychosis.
Comprehensive assessment notes detailing substance use history and mental status.
Psychiatrists should ensure thorough documentation to support the diagnosis.
Key symptoms include hallucinations, delusions, and disorganized thinking that occur during or shortly after inhalant use.
